Han Bio, a Seoul-based firm that develops cell therapies based mostly on pure killer cells and stem cells, final yr developed a expertise that can be utilized within the mass culturing of dermal papilla cells, a inhabitants of cells that play pivotal roles in hair formation, development and biking.
Throughout an interview with The Korea Herald on Friday final week, Kang mentioned with this expertise it might take only a single strand of a affected person’s hair to domesticate sufficient cells to breed round 30,000 hair strands.
Kang added that Han Bio has additionally secured applied sciences to separate and regroup the dermal papilla cells in hair follicles. Every hair follicle accommodates 3,000 dermal papilla cells, and Kang burdened that his firm doesn’t use chemical substances or intrude with the operate of the cells throughout this course of. The applied sciences are patented in Korea.
The chairman added that the corporate is now making ready to use for patents in international international locations together with the US, Japan and China.
“The corporate has not determined how it might enter the abroad markets, however is open to varied choices, together with out-licensing the expertise,” Kang mentioned.
Drawing international sufferers to come back right here is one other means of increasing the corporate’s attain, the chairman mentioned. Sufferers might each journey and obtain hair loss therapy in Korea in a specifically organized package deal journey, in line with Kang.
“The corporate has already secured check outcomes exhibiting that it’s secure for a affected person in different international locations to ship his or her hair prematurely, which the corporate makes use of to domesticate the cells and put together hair transplantation upon the affected person’s arrival right here,” Kang mentioned.
Han Bio has already completed building of its first plant, the place the corporate shops and cultivates sufferers’ dermal papilla cells. Each time a affected person desires, the corporate can regroup 3,000 cultivated dermal papilla cells and transplant them into the recipient.
The ability is at the moment present process a validation course of and expects to begin operation in April or Could, Kang added.
Utilizing the brand new expertise, Han Bio might additionally cut back the price of hair transplantation. “The corporate expects to have the ability to minimize the fee because the period of time required for hair transplantation through the use of our applied sciences is round half of current hair transplantation surgical procedures,” he mentioned.
In Korea, transplantation of a single hair strand sometimes prices round 3,000 gained ($2.65).
Han Bio is at the moment taking steps towards medical research in Korea and is selecting its associate for the trials. The corporate plans to begin its medical research within the second half of this yr, after submitting the mandatory paperwork to the authorities.
Kang mentioned he anticipated the time required for medical trials to be shortened below a brand new legislation right here, which grew to become efficient Aug. 28 final yr, designed to assist fast-track the market entry of regenerative medicines and biologic medicine.
In the meantime, Han Bio would additionally collaborate with native information and synthetic intelligence firms to construct a system that would analyze giant well being data for correct analysis and illness prevention, Kang mentioned.
By Shim Woo-hyun (firstname.lastname@example.org)